Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Conditions
Interventions
INCB053914
I-DAC (Intermediate dose cytarabine)
+2 more
Locations
19
United States
The University of Arizona Cancer Center
Tucson, Arizona, United States
UC Davis comprehensive Cancer Center
Sacramento, California, United States
UCLA Medical Hematology & Oncology
Santa Monica, California, United States
Yale University
New Haven, Connecticut, United States
Mayo Clinic Florida
Jacksonville, Florida, United States
Florida Cancer Specialists & Research Institute
Sarasota, Florida, United States
Start Date
December 29, 2015
Primary Completion Date
August 11, 2020
Completion Date
August 11, 2020
Last Updated
December 8, 2021
NCT06898450
NCT06658951
NCT05719558
NCT05101070
NCT06716138
NCT06307795
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions